{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:29:52Z","timestamp":1794590992078,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KG2129"],"award-info":[{"award-number":["01KG2129"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatic ductal carcinoma (PDAC) is the fourth most frequent cause of cancer-related death in the Western world, and its incidence is rising. In patients that undergo curative resection, local recurrence (LR) is frequent. A recently described surgical technique of extended pancreatoduodenectomy (PD) termed the TRIANGLE operation has been proposed as a promising approach to reduce LR and improve disease-free survival in PDAC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The TRIANGLE trial is a multicentre confirmatory randomised controlled superiority trial with two parallel study groups. A total of 270 patients with suspected or histologically confirmed pancreatic head cancer scheduled for PD will be included in the trial and randomly assigned to the intervention group (extended PD defined as Inoue level 3 dissection along the superior mesenteric and celiac artery as well as removal of all soft tissue in the so-called triangle between the celiac artery, the SMA and the mesenterico-portal axis) or the control group (conventional PD with lymphadenectomy and removal of soft tissue according to current guidelines). The primary endpoint of the trial will be the disease-free survival of patients. Other perioperative outcomes as well as oncological parameters and patient-reported outcomes will be analysed as secondary outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Despite multimodal treatment, LR remains high and disease-free survival is limited following PD for PDAC. The TRIANGLE operation could address these shortcomings of conventional PD as indicated in several retrospective studies. However, this technique could be associated with more adverse events for patients including intractable diarrhoea. The TRIANGLE trial will close the evidence gap as well as offer a risk-benefit assessment of this more radical approach to PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>German Clinical Trials Register DRKS00030576 (UTN U1111-1243-4412) 19th December 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07337-6","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:04:34Z","timestamp":1685437474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Conventional partial pancreatoduodenectomy versus an extended pancreatoduodenectomy (triangle operation) for pancreatic head cancers\u2014study protocol for the randomised controlled TRIANGLE trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Patrick","family":"Heger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Hackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus K.","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fei\u00dft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"D\u00f6rr-Harim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedhelm","family":"M\u00f6hlenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-657X","authenticated-orcid":false,"given":"Andr\u00e9 L.","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"7337_CR1","unstructured":"Robert-Koch Institut, Zentrum f\u00fcr Krebsregisterdaten, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. Krebs in Deutschland 2017\/2018.13. edition, Berlin 2021. Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2021\/krebs_in_deutschland_2021.pdf?__blob=publicationFile"},{"key":"7337_CR2","unstructured":"American Cancer Society. American Cancer Society. Cancer Facts & Figures. Atlanta; 2023. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html"},{"issue":"11","key":"7337_CR3","doi-asserted-by":"publisher","first-page":"e476","DOI":"10.1016\/S1470-2045(13)70172-4","volume":"14","author":"W Hartwig","year":"2013","unstructured":"Hartwig W, Werner J, J\u00e4ger D, Debus J, B\u00fcchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14(11):e476-485.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7337_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.sla.0000217673.04165.ea","volume":"244","author":"JL Cameron","year":"2006","unstructured":"Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10\u20135.","journal-title":"Ann Surg"},{"issue":"1","key":"7337_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1477-2574.2012.00571.x","volume":"15","author":"R Lewis","year":"2013","unstructured":"Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, et al. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15(1):49\u201360.","journal-title":"HPB (Oxford)"},{"key":"7337_CR6","doi-asserted-by":"crossref","unstructured":"Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019","DOI":"10.1016\/j.hpb.2020.04.310"},{"key":"7337_CR7","doi-asserted-by":"crossref","unstructured":"Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019","DOI":"10.1002\/bjs.11295"},{"key":"7337_CR8","unstructured":"AWMF. S3-Leitlinie zum exokrinen Pankreaskarzinom. Langversion. AWMF-Registernummer: 032 - 010OL, 31.12.2021 Available from: https:\/\/register.awmf.org\/assets\/guidelines\/032-010OLl_Exokrines-Pankreaskarzinom_2022-12.pdf"},{"issue":"4","key":"7337_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1245\/s10434-013-3338-2","volume":"21","author":"RP Merkow","year":"2014","unstructured":"Merkow RP, Bilimoria KY, Bentrem DJ, Pitt HA, Winchester DP, Posner MC, et al. National assessment of margin status as a quality indicator after pancreatic cancer surgery. Ann Surg Oncol. 2014;21(4):1067\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7337_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/SLA.0000000000001731","volume":"265","author":"O Strobel","year":"2017","unstructured":"Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, J\u00e4ger D, Schirmacher P, Hackert T, B\u00fcchler MW. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265(3):565\u201373.","journal-title":"Ann Surg"},{"issue":"10","key":"7337_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/bjs.5397","volume":"93","author":"CS Verbeke","year":"2006","unstructured":"Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232\u20137.","journal-title":"Br J Surg"},{"issue":"6","key":"7337_CR12","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1245\/s10434-008-9839-8","volume":"15","author":"I Esposito","year":"2008","unstructured":"Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"7337_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/SLA.0000000000001065","volume":"262","author":"Y Inoue","year":"2015","unstructured":"Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, et al. Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach. Ann Surg. 2015;262(6):1092\u2013101.","journal-title":"Ann Surg"},{"issue":"11","key":"7337_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.hpb.2017.07.007","volume":"19","author":"T Hackert","year":"2017","unstructured":"Hackert T, Strobel O, Michalski CW, Mihaljevic AL, Mehrabi A, M\u00fcller-Stich B, et al. The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford). 2017;19(11):1001\u20137.","journal-title":"HPB (Oxford)"},{"issue":"3","key":"7337_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.hpb.2021.06.432","volume":"24","author":"R Klotz","year":"2022","unstructured":"Klotz R, Hackert T, Heger P, Probst P, Hinz U, Loos M, et al. The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes. HPB (Oxford). 2022;24(3):332\u201341.","journal-title":"HPB (Oxford)"},{"issue":"10073","key":"7337_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, European Study Group for Pancreatic Cancer, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324.","journal-title":"Lancet"},{"issue":"11","key":"7337_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, European Study Group for Pancreatic Cancer, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154(11):1038\u201348.","journal-title":"JAMA Surg"},{"issue":"8","key":"7337_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/bjs.11115","volume":"106","author":"WS Tummers","year":"2019","unstructured":"Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106(8):1055\u201365.","journal-title":"Br J Surg"},{"issue":"1","key":"7337_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1245\/s10434-020-08600-9","volume":"28","author":"CA McIntyre","year":"2021","unstructured":"McIntyre CA, Zambirinis CP, Pulvirenti A, Chou JF, Gonen M, Balachandran VP, et al. Detailed analysis of margin positivity and the site of local recurrence after pancreaticoduodenectomy. Ann Surg Oncol. 2021;28(1):539\u201349. https:\/\/doi.org\/10.1245\/s10434-020-08600-9. (Epub 2020 May 25).","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"7337_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/bjs.8763","volume":"99","author":"P Sanjay","year":"2012","unstructured":"Sanjay P, Takaori K, Govil S, Shrikhande SV, Windsor JA. \u201cArtery-first\u201d approaches to pancreatoduodenectomy. Br J Surg. 2012;99(8):1027\u201335.","journal-title":"Br J Surg"},{"issue":"3","key":"7337_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.surg.2014.06.016","volume":"156","author":"JAMG Tol","year":"2014","unstructured":"Tol JAMG, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591\u2013600.","journal-title":"Surgery"},{"key":"7337_CR22","unstructured":"FDA Commissioner O of the. Clinical trial endpoints for the approval of cancer drugs and biologics. 2018 [Cited 2019 Oct 25]. Available from: http:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"},{"key":"7337_CR23","volume-title":"Guideline on the evaluation of anticancer medicinal products in man","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. 2012."},{"issue":"25","key":"7337_CR24","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"issue":"2","key":"7337_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147\u201356.","journal-title":"JAMA"},{"issue":"3","key":"7337_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","volume":"161","author":"C Bassi","year":"2017","unstructured":"Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, International Study Group on Pancreatic Surgery (ISGPS), et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161(3):584\u201391.","journal-title":"Surgery"},{"issue":"1","key":"7337_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.surg.2007.02.001","volume":"142","author":"MN Wente","year":"2007","unstructured":"Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1):20\u20135.","journal-title":"Surgery"},{"issue":"5","key":"7337_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.surg.2007.05.005","volume":"142","author":"MN Wente","year":"2007","unstructured":"Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761\u20138.","journal-title":"Surgery."},{"issue":"5","key":"7337_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.surg.2010.12.002","volume":"149","author":"M Koch","year":"2011","unstructured":"Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011;149(5):680\u20138.","journal-title":"Surgery"},{"issue":"2","key":"7337_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.surg.2016.06.058","volume":"161","author":"MG Besselink","year":"2017","unstructured":"Besselink MG, van Rijssen LB, Bassi C, Dervenis C, Montorsi M, Adham M, et al. Definition and classification of chyle leak after pancreatic operation: a consensus statement by the International Study Group on Pancreatic Surgery. Surgery. 2017;161(2):365\u201372.","journal-title":"Surgery"},{"key":"7337_CR31","unstructured":"CTCAE. Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. [Cited 2019 Oct 8]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"issue":"2","key":"7337_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187\u201396.","journal-title":"Ann Surg"},{"key":"7337_CR33","doi-asserted-by":"crossref","unstructured":"Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncol. 2019","DOI":"10.1016\/j.ejso.2019.04.007"},{"issue":"9938","key":"7337_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(14)60238-5","volume":"384","author":"MK Diener","year":"2014","unstructured":"Diener MK, Knebel P, Kieser M, Schuler P, Schiergens TS, Atanassov V, et al. Effectiveness of triclosan-coated PDS Plus versus uncoated PDS II sutures for prevention of surgical site infection after abdominal wall closure: the randomised controlled PROUD trial. Lancet. 2014;384(9938):142\u201352.","journal-title":"Lancet"},{"issue":"5","key":"7337_CR35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/SLA.0000000000000954","volume":"260","author":"AL Mihaljevic","year":"2014","unstructured":"Mihaljevic AL, Schirren R, Ozer M, Ottl S, Grun S, Michalski CW, et al. Multicenter double-blinded randomized controlled trial of standard abdominal wound edge protection with surgical dressings versus coverage with a sterile circular polyethylene drape for prevention of surgical site infections a CHIR-Net trial (BaFO; NCT01181206). Ann Surg. 2014;260(5):730\u20137 (discussion 7-9).","journal-title":"Ann Surg"},{"issue":"4","key":"7337_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/SLA.0b013e31819ec6c8","volume":"249","author":"CM Seiler","year":"2009","unstructured":"Seiler CM, Bruckner T, Diener MK, Papyan A, Golcher H, Seidlmayer C, et al. Interrupted or continuous slowly absorbable sutures for closure of primary elective midline abdominal incisions: a multicenter randomized trial (INSECT: ISRCTN24023541). Ann Surg. 2009;249(4):576\u201382.","journal-title":"Ann Surg"},{"issue":"2","key":"7337_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"6","key":"7337_CR38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977\u201388.","journal-title":"Surgery"},{"key":"7337_CR39","doi-asserted-by":"crossref","unstructured":"Tempero, Mp M, Sw B, 3rd BA, Es C, Eg C, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Comprehensive Cancer Netw. 2014;12(8):1083\u201393.","DOI":"10.6004\/jnccn.2014.0106"},{"issue":"Suppl 7","key":"7337_CR40","doi-asserted-by":"publisher","first-page":"vii33","DOI":"10.1093\/annonc\/mds224","volume":"23","author":"T Seufferlein","year":"2012","unstructured":"Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii33-40.","journal-title":"Ann Oncol"},{"issue":"12","key":"7337_CR41","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/bjs.10221","volume":"103","author":"W Hartwig","year":"2016","unstructured":"Hartwig W, Gluth A, Hinz U, Koliogiannis D, Strobel O, Hackert T, et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br J Surg. 2016;103(12):1683\u201394.","journal-title":"Br J Surg"},{"key":"7337_CR42","unstructured":"Mihaljevic AL, Kleeff J, Friess H. Adenocarcinoma of the pancreas. In: Surgical management of hepatobiliary and pancreatic disorders. Graeme J. Poston, Michael D\u2019Angelica, Ren\u00e9 Adam. London: Informa Healthcare; 2011. 380\u2013400."},{"key":"7337_CR43","unstructured":"World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects. Adopted by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013 Available from: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/"},{"key":"7337_CR44","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH E6. Harmonised guideline for good clinical practice. 1996. Available from: https:\/\/www.ich.org\/page\/efficacy-guidelines"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07337-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T09:11:54Z","timestamp":1685437914000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07337-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7337"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07337-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TRIANGLE trial is conducted according to the Medical Association\u2019s professional code (Berufsordnung der Bundes\u00e4rztekammer) \u00a715. To ensure the patient\u2019s rights and safety, the responsible investigator will ensure that the trial will be conducted according to the ethical principles laid out in the Declaration of Helsinki []. Before participation in the TRIANGLE trial, written informed consent will be obtained from all study participants. This protocol is designed to ensure that the trial will be conducted and analysed in accordance with ICH-GCP E6 []. The protocol has already been approved by the IEC of the Medical Faculty of the University of Ulm, and secondary approval of the corresponding ethical bodies of all other participating centres has been or will be obtained. The trial protocol has been formulated in accordance with the recommendations of the SPIRIT guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"363"}}